ABSTRACT
or ["?]T3 (50,000 cpm; 50 PM) in medium with 0.5% BSA. In this medium, the ratio of the free fractions of Triac, TB, and T1 was 1:8:1. Exposure of cells to 100 nM TRH for 2 h stimulated TSH release by 80-110% (P < 0.001). Comparing total hormone levels (1 nM to 1 jtM), Triac and TS were equally effective in reducing this response, and both were lo-fold more effective than T,. Triac uptake by 15% (P < 0.005) and 19% (P c 0.005), respectively.
The data show that 1) Triac, on the basis of the free hormone concentration, is more potent than Tz or T, in suppressing TSH secretion; and 2) the rapid uptake of ['Z51] Triac by the anterior pituitary occurs by a carrier-mediated mechanism that is only partially dependent on ATP or the Na+ gradient. (Endocrinology 136: 2700 (Endocrinology 136: -2707 (Endocrinology 136: , 1994 T HE METABOLISM of T3 occurs by three pathways: deiodination, conjugation, and side-chain alteration. Whereas 50-60% of T3 in humans is deiodinated to 3,3'-diiodothyronine (l), alteration of the alanine side-chain, resulting in the production of 3,3',5-triiodothyroacetic acid (Triac), may account for around 14% of T3 metabolism in man (2). However, under pathological conditions, as, for example, fasting, Triac production is substantially increased (3, 4) . Furthermore, these researchers suggested that Triac might be of importance for the suppression of TSH secretion in fasting, which occurs despite low plasma TJ and T4 levels. Also, under conditions other than fasting, characterized by low plasma TSH, T3, and Tl, Triac might play a role in the suppression of TSH secretion (5).
In euthyroid and hypothyroid subjects, administration of Triac suppresses basal TSH secretion (6-8) as well as the TSH response to TRH (6, 9) . Furthermore, Triac is used in the treatment of patients with thyroid cancer (10, 11) and generalized resistance to thyroid hormones (12, 13). However, the question of whether the effects of Triac are specific for the pituitary gland has not been definitively answered (8, 9, 11, 14) .
Early in vitro studies showed that T3 and Triac were equally potent in the suppression of TSH production and displacement of [lz51]T3 from the nuclear binding sites in mouse thyrotropic tumor cells (15). In rat pituitary fragments superfused with BSA-containing medium, both 0.1 PM Triac and 0.1 PM TS reduced the TRH-induced TSH release by around 25% (16).
Previously, we reported evidence for carrier-mediated uptake of T3 and Tq in cultured anterior pituitary cells of euthyroid rats (17, 18) . Moreover, T3 and T4 seem to share the same carrier in the pituitary (18, 19) . The purpose of the present work was to study 1) the effect of Triac, compared to those of T3 and T4, on basal and TRH-induced TSH release; and 2) the mechanism of uptake of ['251 After incubation, cells were washed once with ice-cold saline (0.9% NaCl). The cells were harvested from the wells with a rubber policeman in 1 ml PBS (on ice) and counted for 30 sec. Isotope uptake, calculated as a percentage of the dose with this method, gave similar values for the cellular radioactivity as the usual procedure with 0.1 N NaOH. All of the following procedures were performed on ice. A cell pellet was obtained after centrifugation (300 X g; 4 C; 7 mm), counted (30 set), and solubilized in 1 ml PBS containing 0.5% Triton X-100, as previously described (23). After 2 rnin of continuous vortexing, nuclei were spun down (900 x g; 4 C; 5 min) and washed once with 1 ml PBS containing 0.5% Triton X-100. The nuclear pellets were counted for 5 min.
LH-20 chromatography
Aliquots of the incubation medium were chromatographed on Sephadex . Iodide was eluted from the column with 4 x 1 ml 0.1 N HCI. Subsequently, possible conjugates were eluted eight times with 1 ml HrO, and finally, the remaining Triac or T3 was eluted from the column four times with 1 ml 50% ethanol in 0.1 N NaOH. To determine the TSH content of cells, 0.5 ml incubation medium was added to the wells. The cells were scraped from the wells with a rubber policeman, and the wells were sonicated twice for 30 sec. The extracts were removed, and the wells were washed once with 0.5 ml medium.
TSH release and cellular content
The two fractions were then combined (volume of cell extract, 1.0 ml) and centrifuged (2000 X g) at room temperature, and the supematant was frozen until further analysis,
After removal of the culture medium, cells were preincubated with 0.5 ml incubation medium. The incubation medium was identical to the culture medium, except that the fetal calf serum was replaced by 0.1% or 0.5% BSA. Preincubation was carried out for 30 min at 37 C in the absence or presence of 10 PM oligomycine, MDC, or monensin. The medium was removed after preincubation, and incubation was started with 0.25 ml medium containing the same additions as those described above, 10 nM to 10 PM Triac, or 10 PM T,, TI, or Tetrac and in all cases ['rsI with 0.5% BSA, the free fractions of Triac, TS, and TI were 0.47 + 0.03% (n = 5), 3.45 + 0.05% (n = 4), and 0.41 f 0.03% (n = 5), respectively.
In rat serum, the free fractions of Triac, T,, and TI were 0.028%, 0.381%, and 0.025%, respectively. The free Triac or TB fraction in 0.5% BSA did not change after the addition of 10 nM or 1 PM unlabeled Triac.
Incubations lasting for more than 1 h were performed at 37 C in humidified air with 5% COZ. Incubations of shorter duration took place in a 37 C incubation chamber on a rotating device without COZ. Therefore, the NaHC03 in the culture medium was replaced by an equimolar amount of HEPES (8.9 mM), piperazine-NJ'-bis-[2-ethane sulfonic acid] (10.6 m) and NJ-bis-[2-hydroxyethyl]2-aminoethane sulfonic acid (11.2 mM).
After incubation, the medium was removed, and the cells were washed with l-ml volumes of ice-cold saline to remove tracer not bound to the cells. Cells were dissolved in 1 ml 0.1 N NaOH and counted for '? activity in a 16-channel y-counter (NE 1600, Nuclear Enterprises,
In medium with 0.1% BSA, the free fraction of Triac was 1.84 f 0.07% (n = 9). This value did not change after the addition of 10 nM
at Medical Library Erasmus MC on January 2, 2007 endo.endojournals.org Downloaded from Endo -1994 Voll35. No 6 Triac (1.75 + 0.06%; n = 5), but it increased after the addition of 10 PM Triac, TS, Tq, or Tetrac to 2.55 + 0.07% (n = 5), 2.04 + 0.05% (n = 3), 2.15 f 0.06% (n = 3), and 2.42% (n = 2), respectively.
The free Triac fractions (in 0.1% BSA) in the presence of 10 PM MDC, oligomycin, or monensin were 1.77 f 0.07% (n = 5), 1.76 + 0.10% (n = 5), and 1.83 + 0.13% (n = 5), respectively. 
ATP determination

Results
TSH release during culture
To determine whether TX, Tq, or Triac affected basal TSH release from cultured anterior pituitary cells, these three hormones were added at a concentration of 10 nM to cells cultured in medium supplemented with absorbed fetal calf serum. In addition, the effects of rT3 (10 nM) and TRH (1 nM) were tested (Table 1 ). The inhibitory effect of the thyroid hormones or analogs on basal TSH secretion during 3 days of culture decreased in the order Triac > T3 > T4 > rT3. The presence of 1 nM TRH almost doubled TSH release. In two separate experiments, it was found that total TSH (released into the medium plus cellular content) increased by 65% (P < 0.001) after culture in the presence of 1 nM TRH (not shown).
TSH release during short term exposure to TRH The effects of Triac, Ts, and T4 were also compared with respect to inhibition of TRH-induced TSH release during short (2-h) incubation experiments. As shown in Table 2 , TSH release increased by around 80% after exposure to 100 nM TRH. At the same time, the cellular TSH content decreased proportionally, suggesting that TRH stimulated the release of stored TSH (not shown). The stimulating effect of TRH on TSH release was almost completely blocked by preincubation and incubation with 10 nM or 1 PM T3 or Triac (Table 2) .
In two experiments, we compared the effects of Triac and T4 at a concentration of 25 nM on TRH-induced TSH release. TSH release (4.20 + 0.37 ng; n = 9) was stimulated 2-fold after exposure to 100 nM TRH (8.73 + 0.25 ng; n = 9; +108%; P < 0.001). After preincubation for 2 h with 25 nM Triac or T4, TSH release was 4.92 + 0.25 ng (n = 6) and 5.96 + 0.49 ng (n = 6), respectively (0.05 < P < 0.10).
Finally, we tested within one experiment the effects of Triac, T3, and T4 on TRH-induced TSH release at lower concentrations than those of the previous series. The results shown in Table 3 demonstrate that at concentrations of 1, 2.5, and 10 nM, T3 and Triac were equally potent in suppression of the TRH-induced TSH release. Tl, however, had no significant inhibitory effect at a concentration of 2.5 nM. The effect of T4 increased with higher concentrations, and the effect of 100 nM T, was approximately as large as that of 10 nM T3 or Triac. and the effect was largest after 4 h [89% for [iz51]Triac (P < 0.001; n = 6) and 63% for [1251]T3 (P < 0.001; n = 6)]. It is evident from the upper curves in Fig. 1, A and incubation (60 min) were performed as described in Fig. 1 , except that half of the incubations contained 10 nM unlabeled Triac. Bars represent the mean f SE of six observations from two independent experiments. *, P < 0.001, 10 nM Triac us. no additions. Data show the means of triplicate observations in a single experiment. Anterior pituitary cells were cultured for 3 days at a density of 800,000 cells/well. Preincubation (30 min) and incubation (1 h) for determination of [iz51]Triac uptake (200,000 cpm) were carried out in medium with 0.1% BSA, and for determination of ["'I]T, uptake (100,000 cpm) in medium with 0.5% BSA. Unlabeled Triac or T, (10 PM) was only present during incubation. Total uptake was measured in cells scraped from the wells in 1 ml PBS. After centrifugation of the suspension, a cell pellet was obtained and counted. The nuclear pellet was obtained after treatment with Triton X-100 (for further details, see Materials and Methods). Corrected for the free hormone concentration, the 15min [1251]Triac uptake in 0.5% BSA was 0.245 + 0.021 fmol/pM free Triac (n = 8), and that in 0.1% BSA was 0.231 f 0.008 fmol/pM free Triac (n = 8; P = NS). Therefore, the 15-min uptake experiments were performed in medium with 0.1% BSA. Figures 3 and 4 show the results of four experiments, in which the competitive effects of various concentrations of unlabeled Triac, TJ, T4, or Tetrac were tested. The presence of 10 nM Triac resulted in significantly lower uptake of [1251] Triac (35%; P < O.OOl), whereas 10 PM Triac produced a maximal inhibitory effect of 56% (P < 0.001; Fig. 3) . A similar inhibitory effect on ['251]Triac uptake was obtained in the presence of 10 PM TJ, T4, or Tetrac (Fig. 4) . When [1251]T3 uptake was measured in the presence of 10 PM TJ, T4, Triac, or Tetrac, uptake was reduced by 70%, 60%, 47%, and 48%, days at a density of 500,000 cells/well. Experiments were performed as described in Fig. 3 , without or with 10 PM Triac, Ta, T,, or Tetrac present during the incubation. Bars represent the mean f SE of six to nine observations from three independent experiments. *, P < 0.001 vs. no additions.
respectively (all P < 0.001). Preincubation and incubation with MDC, oligomycin, and monensin, can be used to study the possible involvement of receptor-mediated endocytosis, energy dependence, and the dependence of the uptake process on the Na+ gradient, respectively (17, 18) . When tested at a concentration of 10 PM, MDC reduced the 15-min uptake of [1251] Triac by 19% (n = 11; P < 0.005), oligomycin reduced it by 23% (n = 11; P < O.OOl), and monensin reduced it by 15% (n = 11; P < 0.005; Fig. 5) .
Finally, the 15-min uptake of ['251]Triac was directly compared with that of [lz51]T 3 with respect to the energy dependence and temperature dependence of the uptake process. Under control conditions, the uptake of In the 2-h incubation experiments with TRH, Triac was, on the basis of the total hormone concentration, equally potent as TJ in suppression of the TRH-induced TSH release. To obtain a similar effect with Tq, at least a lo-fold higher total dose was required compared to Triac or TJ. However, when the difference in the free fractions of Triac, TS, and T4 is taken into account (ratio of the free fractions, 1:8:1), the order of potency for inhibition of TRH-induced TSH release appears to be Triac > T3 > Tq, A significant reduction of the TSH response to TRH was seen with concentrations as low as 1 nM Triac or TJ. The anterior pituitary cell preparation may be more sensitive to demonstrate these effects than superfused pituitary fragments (16). In the latter system, 100 nM Triac or T3 (in medium with 0.25% BSA) was required to significantly reduce the TSH response to TRH.
It has been demonstrated in viva that T3 or T, injected into hypothyroid rats reduced the plasma TSH level within 2 h (26). This effect was related to nuclear binding of TJ (26) and probably reflects interference with the TSH release process. On the other hand, when pituitary cells were exposed for a prolonged period of time (1-3 days during culture) to Triac, TB, Tq, or TRH, the results were more likely to reflecthinterference with TSH synthesis. This idea was supported by the finding that the total TSH (medium plus cells) was significantly increased after culture in the presence of 1 nM TRH, suggesting de nova TSH synthesis, which confirmed the early Endo. 1994 Voll35. No 6 results of Vale et al. (27) . Triac seemed to be the most effective in suppression of TSH release during culture. Addition of the same total concentration of T4 (10 nM) showed a smaller effect on TSH release than that obtained with T3 or Triac after both 1 and 3 days of culture. When it is taken into account that in medium with 10% serum, the free Triac fraction is much lower than that of TJ, Triac is the most effective in inhibition of TSH synthesis. This was also observed in thyrotropic tumor cells cultured in the presence of serum, when thyroid hormones or analogs were added for 24 h (15). In that study, T3 and Triac were equally potent when total hormone concentrations were compared, and both showed a IO-fold higher potency than T4.
Both (and T4) . This could mean that Triac is partly taken up by the anterior pituitary by the same transport mechanism as that for T3 and T4 and partly by another transport system. When Triac is used to suppress TSH secretion in patients, it has to be administered in relatively large doses (9-l 1) due to its short half-life (-6 h) (7). This idea is supported by the observation that dividing the daily Triac dose into four parts had a more pronounced effect on serum TSH in euthyroid subjects than a single dose (8). One of the factors that could explain the short half-life of Triac in humans is the recent finding that Triac is extremely rapidly glucuronidated in the liver (31). It was recently suggested that Triac might be of importance in the euthyroid sick syndrome (3-5). This syndrome is characterized by low serum TJ and T4 levels without a rise in serum TSH (32). The normal serum level of Triac is about 50 PM (2) compared to a normal serum T3 level of 2000 PM (26). As the free fraction of Triac in serum is much lower than that of T3 (33), the difference in free hormone concentration in normal subjects may be a factor of 400. During the euthyroid sick syndrome, the serum T3 level may drop as much as 50%, with a concomitant decrease in the free TJ concentration (32). In contrast to TS, Triac is strongly bound to prealbumin in serum, and the prealbumin level decreases substantially during illness (5), leading to a rise in the free Triac fraction (3-to 9-fold) (Everts, M. E., and T. J. Visser, unpublished). This effect should be added to an increased Triac production, whereas deiodination of T4 to TJ is diminished (3, 4). Together with our observations that the thyrotroph seems to be more sensitive to Triac than to TJ and the fact that the uptake of Triac is higher than that of TJ, it is possible that Triac plays a role in the control of TSH secretion in the euthyroid sick syndrome.
